R&D | January 21, 2026
Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The study evaluated patients with stage III/IV melanoma after complete tumor resection
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
The initiative pairs consumer engagement with a public health message about prevention and early detection
Pharma giant targets new standards of care
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Subscribe To Our Newsletter & Stay Updated
